2784. Rates of Susceptibility and Heteroresistance to Novel Antibiotic Combinations in Carbapenem-Resistant Enterobacterales Isolates - Emory Healthcare, 2016-2021

BACKGROUND: CRE infections are frequently treated with new beta-lactam/beta-lactamase inhibitors (BL/BLI): imipenem-relebactam (I-R), ceftazidime-avibactam (CZA), and meropenem-vaborbactam (MVB). However, the frequency of susceptibility and heteroresistance (HR), defined as the presence of an antibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Christina K, Page, Alex M, Lohsen, Sarah, Babiker, Ahmed, Jacob, Jesse T, Satola, Sarah W, Howard-Anderson, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677691/
http://dx.doi.org/10.1093/ofid/ofad500.2395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677691/
http://dx.doi.org/10.1093/ofid/ofad500.2395

Ejemplares similares